MedTrace Logo

Abobotulinumtoxina Efficacy in Post-Traumatic Headache

NCT03928496 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2019-04-26

No results posted yet for this study

Summary

This study will evaluate the efficacy of abobotulinumtoxina on Veterans with post-traumatic headache

Conditions

  • Post-Traumatic Headache

Interventions

DRUG

AbobotulinumtoxinA

Subjects were injected with 0.1 ml (12.5 units of Abobotulinumtoxina) into 31 distinct muscle locations in the head and neck

DRUG

Normal saline

Subjects were injected with 0.1 ml of preservative free normal saline into 31 distinct muscle locations in the head and neck

Sponsors & Collaborators

  • Ipsen

    collaborator INDUSTRY

  • VA Greater Los Angeles Healthcare System

    lead FED

Principal Investigators

  • Milena Zirovich, MD · VA Greater Los Angeles

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-08-01
Primary Completion
2017-02-02
Completion
2017-02-02
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03928496 on ClinicalTrials.gov